ATOSIBAN STRAGEN 6.75 mg/0.9 ml, solution for injection bottle, 0.9 ml
Active ingredients: Atosiban acetate, Atosiban
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Solution for injectionbottle, 0.9 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ATOSIBAN STRAGEN 6,75 mg/0,9 ml, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 0,9 ml
- Marketing authorisation holder
- STRAGEN-FRANCE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 31 Jul 2022
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Hospital use only
- Emergency use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69966888CIP75503111CIP133400955031116Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ATOSIBANsolution | 6,75 mg · 0,9 ml de solution | FT |
| ACÉTATE D'ATOSIBANsolution | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.